Journal Article

Epidemic features and megagenomic analysis of childhood Mycoplasma pneumoniae post COVID-19 pandemic: a 6-year study in southern China

Lian, Jiacee, Wu, Jianlong, Zhang, Xiaoxian, Huang, Li, Sun, Panpan, Wang, Jinping, Xu, Yi, Wu, Xiaohuan, Lian, Qizhou, Fang, Chunxiao, Gu, Yiling, Yang, Chen, Wang, Qian, Yang, Juhua, Zhang, Jinqiu, Yang, Bin, Zhang, Che, Zhang, Hongwei, Zeng, Fansen

2024

Overview

With the atypical rise of infection (MPI) in 2023, prompt studies are needed to determine the current epidemic features and risk factors with emerging trends of MPI to furnish a framework for subsequent investigations. This multicentre, retrospective study was designed to analyse the epidemic patterns of MPI before and after the COVID-19 pandemic, as well as genotypes and the macrolide-resistance-associated mutations in sampled from paediatric patients in Southern China. Clinical data was collected from 1,33,674 patients admitted into investigational hospitals from 1 June 2017 to 30 November 2023. Metagenomic next-generation sequencing (mNGS) data were retrieved based on sequence positive samples from 299 paediatric patients for macrolide-resistance-associated mutations analysis. was used to compare categorical variables between different time frames. The monthly average cases of paediatric common respiratory infection diseases increased without enhanced public health measures after the pandemic, especially for influenza, respiratory syncytial virus infection, and MPI. The contribution of MPI to pneumoniae was similar to that in the outbreak in 2019. Compared to mNGS data between 2019-2022 and 2023, the severity of did not grow stronger despite higher rates of macrolide-resistance hypervariable sites, including loci 2063 and 2064, were detected in childhood samples of 2023. Our findings indicated that ongoing surveillance is necessary to understand the impact of post pandemic on transmission disruption during epidemic season and the severity of clinical outcomes in different scenarios.

• Publisher: Taylor & Francis Ltd,Taylor & Francis Group
• Subject: Adolescent / Anti-Bacterial Agents - pharmacology / Antibiotics / Child / Child, Preschool / Childhood / China - epidemiology / COVID-19 / COVID-19 - epidemiology / COVID-19 - transmission / Disease transmission / Drug Resistance, Bacterial / Epidemics / Female / High-Throughput Nucleotide Sequencing / Humans / Infant / Infections / macrolide-resistance-associated mutation / Macrolides - pharmacology / Male / Mutation / Mycoplasma pneumoniae / Mycoplasma pneumoniae - drug effects / Mycoplasma pneumoniae - genetics / Mycoplasma pneumoniae - isolation & purification / paediatric infectious diseases / Pandemics / Pediatrics / Pneumonia, Mycoplasma - epidemiology / Pneumonia, Mycoplasma - microbiology / post COVID-19 pandemic / public health measure / Retrospective Studies / SARS-CoV-2 - genetics / SARS-CoV-2 - isolation & purification